Fenofibrate [orch, phsu]
Decrease [qlco]
Plasma [bdsu]
Fibrinogen [aapp, bacs, phsu]
Lipid [lipd]
Profile [lbpr]
Plasma [bdsu]
Fibrinogen [aapp, bacs, phsu]
cardiovascular risk factor [dsyn]
Trial [resa]
Design [acty]
Fenofibrate [orch, phsu]
Fibrinogen [aapp, bacs, phsu]
secondary [neop]
End Point [qlco]
Lipid [lipd]
Profile [lbpr]
Uric Acid [bacs, orch]
Patients [podg]
Dyslipidaemia [dsyn]
Subject [grup]
Women [popg]
Men [popg]
admitted [hlca]
Active [ftcn]
Group [idcn]
Seven [qnco]
Sole [blor]
Hypercholesterolaemia [dsyn]
Subject [grup]
Mixed [ftcn]
Dyslipidaemia [dsyn]
Attributable [menp]
Fenofibrate [orch, phsu]
Decrease [qlco]
Fibrinogen [aapp, bacs, phsu]
Ratio [qnco]
Low Density Lipoprotein Cholesterol [bacs, strd]
High Density Lipoprotein Cholesterol [bacs, lipd]
Low Density Lipoprotein Cholesterol [bacs, strd]
High Density Lipoprotein Cholesterol [bacs, lipd]
Triglycerides [bacs, lipd]
Uric Acid [bacs, orch]
P NOS [aapp, imft]
Fenofibrate [orch, phsu]
simultaneously [tmco]
Affected [ftcn]
Haemostasis [ortf]
lowering [spco]
Lipid [lipd]
Profile [lbpr]
Fenofibrate [orch, phsu]
Few [qnco]
adverse effects [ftcn]
Fair [qlco]
Option [ftcn]
Patients [podg]
Need [qlco]
resins [bodm]
Niacin [orch, phsu, vita]
Efficacy [qlco]
tested [inpr]
Study [mnob]
Real [qlco]
Capacity [qnco]
PREVENT [phsu]
cardiovascular events [fndg]
